Ardelyx is a biopharmaceutical company focused on developing medicines for people with cardiorenal diseases. This includes patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus; and CKD patients and/or heart failure patients with elevated serum potassium (hyperkalemia).Co.'s product pipeline includes the following: Tenapanor, an approach for the control of serum phosphorus in CKD patients on dialysis; DX013 Program, a small molecule for treating hyperkalemia; and IBSRELA? (tenapanor) a treatment for irritable bowel syndrome with constipation in adults.

CEVA Logistics AG. CEVA Logistics AG is a Switzerland-based company, which is engaged in the designing and implementing industry solutions in both freight management and contract logistics. The Company divides its business activities into two segments. Freight Management segment, which includes the provision of international air, ocean, ground, customs brokerage, deferred air, pickup and delivery, and other services. Contract Logistics segment includes the provision of inbound logistics, manufacturing support, outbound and distribution logistics, and aftermarket logistics. The Company designs, implements and operates end-to-end complete supply chain solutions for multinational and large and medium sized companies on a national, regional and global level. It also offers a flexible range of Ocean Freight services for both Less-Than-Container Load (LCL) and Full-Container Load (FCL) shipments.

Conduent is a holding company. Through its subsidiaries, the company is a provider of business process services in transaction-intensive processing, analytics and automation. The company's Commercial Industries segment provides business process services and customized solutions to clients in a variety of industries. The company's Government Services segment provides government-centric business process services to U.S. federal, state and local and foreign governments for transportation, public assistance, program administration, transaction processing and payment services. The company's Transportation segment provides systems and support services to transportation departments and agencies globally.

First Financial Bankshares is a financial holding company. Through its subsidiaries, the company conducts commercial banking business. The company's banking centers are located primarily in Central, North Central, Southeast and West Texas. Each of the company's bank regions provides general commercial banking services, which include accepting and holding checking, savings and time deposits, making loans, automated teller machines, drive-in and night deposit services, safe deposit facilities, remote deposit capture, internet banking, mobile banking, payroll cards, transmitting funds, and performing other customary commercial banking services.

Insulet is engaged in the development, manufacturing and sale of its Omnipod? System, an insulin delivery system for people with insulin-dependent diabetes, which consists of two product lines: the Omnipod Insulin Management System and Omnipod DASH? Insulin Management System. The Omnipod System features a self-adhesive disposable tubeless Pod, which is worn on the body and provides up to three days of non-stop insulin delivery without the need to see or handle a needle, and a handheld Personal Diabetes Manager. The Omnipod System communicates wirelessly, provides for automated cannula insertion and eliminates the need for multiple daily injection therapy or the use of pump and tubing.

Lexicon Pharmaceuticals is a biopharmaceutical company. The company is commercializing XERMELO? (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. The company is developing Zynquista? (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 2 diabetes. The company is also developing sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease. The company is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.

Paylocity Holding is a cloud-based provider of payroll and human capital management software solutions for medium-sized organizations. The company's products include: Payroll, which enables clients to automate primary payroll processes and manage compliance in an environment of regulatory complexity; Core HR, which provides a set of HR capabilities enabling clients to manage HR data in a timely manner while impacting employee engagement and culture; Talent, which are designed to processes that attract and retain talent within an organization; and Workforce Management, which enables clients to collect data for employees, improve productivity and help organizations control labor costs.